$DYAI
Dyadic International Inc

2021 Q3 Form 10-Q Financial Statement

#000143774921019688 Filed on August 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2021 Q2 2020 Q2
Revenue $692.9K $937.1K $524.3K
YoY Change 66.43% 78.74% 34.13%
Cost Of Revenue $392.5K $829.5K $624.2K
YoY Change 47.06% 32.88% 93.73%
Gross Profit $300.4K $107.6K -$99.97K
YoY Change 101.02% -207.62% -245.63%
Gross Profit Margin 43.35% 11.48% -19.07%
Selling, General & Admin $1.693M $1.748M $1.480M
YoY Change 3.22% 18.08% -20.86%
% of Gross Profit 563.56% 1624.35%
Research & Development $1.902M $2.209M $1.116M
YoY Change 92.84% 97.93% 36.41%
% of Gross Profit 633.04% 2053.43%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.902M $2.209M $1.116M
YoY Change 92.84% 97.93% 36.41%
Operating Profit -$3.324M -$3.867M -$2.798M
YoY Change 29.02% 38.21% -5.52%
Interest Expense $3.202K $20.90K $146.6K
YoY Change -95.83% -85.74% -44.83%
% of Operating Profit
Other Income/Expense, Net $1.609M $20.90K
YoY Change 1994.46%
Pretax Income -$1.715M -$3.846M -$2.650M
YoY Change -31.39% 45.14% -1.85%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$1.715M -$3.846M -$2.651M
YoY Change -31.38% 45.06% -1.65%
Net Earnings / Revenue -247.54% -410.44% -505.74%
Basic Earnings Per Share -$0.06 -$0.14
Diluted Earnings Per Share -$61.09K -$139.1K -$96.47K
COMMON SHARES
Basic Shares Outstanding 28.08M 27.55M 27.47M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q3 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $22.75M $25.60M $31.83M
YoY Change -25.2% -19.57% -13.72%
Cash & Equivalents $13.66M $14.02M $11.78M
Short-Term Investments $9.087M $11.58M $20.05M
Other Short-Term Assets $570.0K $100.9K $600.0K
YoY Change 35.71% -83.19% 200.0%
Inventory
Prepaid Expenses
Receivables $179.6K $291.4K $564.7K
Other Receivables $74.80K $163.3K $730.0K
Total Short-Term Assets $23.57M $26.16M $33.73M
YoY Change -25.73% -22.44% -11.25%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $284.7K $284.7K $0.00
YoY Change -100.0%
Other Assets $6.143K $6.172K $6.116K
YoY Change 10.53% 0.92% -88.14%
Total Long-Term Assets $290.9K $290.9K $6.116K
YoY Change 5133.03% 4656.07% -99.7%
TOTAL ASSETS
Total Short-Term Assets $23.57M $26.16M $33.73M
Total Long-Term Assets $290.9K $290.9K $6.116K
Total Assets $23.86M $26.45M $33.73M
YoY Change -24.83% -21.6% -15.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $957.8K $2.435M $1.144M
YoY Change -1.94% 112.85% 18.76%
Accrued Expenses $842.5K $594.8K $378.1K
YoY Change 35.74% 57.3% -4.52%
Deferred Revenue $162.7K $258.7K $41.38K
YoY Change 5.74% 525.36% -54.32%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.963M $3.288M $1.638M
YoY Change 12.09% 100.71% 13.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.963M $3.288M $1.638M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.963M $3.288M $1.640M
YoY Change 12.17% 100.52% 13.1%
SHAREHOLDERS EQUITY
Retained Earnings -$59.53M -$57.82M -$46.22M
YoY Change 22.2% 25.1% 21.9%
Common Stock $40.33K $40.33K $39.74K
YoY Change 1.5% 1.5% 0.94%
Preferred Stock
YoY Change
Treasury Stock (at cost) $18.90M $18.90M $18.90M
YoY Change 0.0% 0.0% -0.16%
Treasury Stock Shares
Shareholders Equity $21.90M $23.16M $32.09M
YoY Change
Total Liabilities & Shareholders Equity $23.86M $26.45M $33.73M
YoY Change -24.83% -21.6% -15.82%

Cashflow Statement

Concept 2021 Q3 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$1.715M -$3.846M -$2.651M
YoY Change -31.38% 45.06% -1.65%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$4.334M -$2.398M -$1.900M
YoY Change 211.81% 26.2% 32.87%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $4.006M $2.496M $8.930M
YoY Change -65.02% -72.05% 327.27%
Cash From Investing Activities $4.006M $2.496M $8.930M
YoY Change -65.02% -72.05% 327.27%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -590.0 866.1K 50.00K
YoY Change 1632.28% -66.67%
NET CHANGE
Cash From Operating Activities -4.334M -2.398M -1.900M
Cash From Investing Activities 4.006M 2.496M 8.930M
Cash From Financing Activities -590.0 866.1K 50.00K
Net Change In Cash -329.2K 964.4K 7.080M
YoY Change -103.27% -86.38% 774.07%
FREE CASH FLOW
Cash From Operating Activities -$4.334M -$2.398M -$1.900M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
28079157
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40332659
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39747659
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28079157
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27494157
CY2021Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
12253502
CY2020Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
12253502
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 USD
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2020 dyai Deferred Tax Assets Valuation Allowance Coverage Percent
DeferredTaxAssetsValuationAllowanceCoveragePercent
1 pure
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4799215
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4650390
CY2020Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
12253502
CY2020Q4 us-gaap Treasury Stock Value
TreasuryStockValue
18900000 USD
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14018826 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20637045 USD
CY2021Q2 us-gaap Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
11581911 USD
CY2020Q4 us-gaap Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
8457452 USD
CY2021Q2 us-gaap Interest Receivable Current
InterestReceivableCurrent
163313 USD
CY2020Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
112247 USD
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
291435 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
294199 USD
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
100888 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
280555 USD
CY2021Q2 us-gaap Assets Current
AssetsCurrent
26156373 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
29781498 USD
CY2021Q2 dyai Prepaid Research And Development In Process Current
PrepaidResearchAndDevelopmentInProcessCurrent
284709 USD
CY2020Q4 dyai Prepaid Research And Development In Process Current
PrepaidResearchAndDevelopmentInProcessCurrent
284709 USD
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6172 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6225 USD
CY2021Q2 us-gaap Assets
Assets
26447254 USD
CY2020Q4 us-gaap Assets
Assets
30072432 USD
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2434934 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1013099 USD
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
594803 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
489756 USD
CY2021Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
258748 USD
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
123016 USD
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3288485 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1625871 USD
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
40333 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
39748 USD
CY2021Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
99865825 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
98013079 USD
CY2021Q2 us-gaap Treasury Stock Value
TreasuryStockValue
18929915 USD
CY2020Q4 us-gaap Treasury Stock Value
TreasuryStockValue
18929915 USD
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-57817474 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-50676351 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
23158769 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
28446561 USD
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
26447254 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
30072432 USD
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
937092 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
524271 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1397612 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
839643 USD
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
829504 USD
CY2020Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
624240 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1220266 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
902422 USD
CY2021Q2 dyai Provision For Contract Losses
ProvisionForContractLosses
0 USD
CY2020Q2 dyai Provision For Contract Losses
ProvisionForContractLosses
74955 USD
dyai Provision For Contract Losses
ProvisionForContractLosses
0 USD
dyai Provision For Contract Losses
ProvisionForContractLosses
74955 USD
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2209242 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1116163 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4017340 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1871616 USD
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1747614 USD
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1475232 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3301621 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3128624 USD
CY2021Q2 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-17806 USD
CY2020Q2 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-31690 USD
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-46078 USD
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-42557 USD
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
4804166 USD
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
3322280 USD
us-gaap Costs And Expenses
CostsAndExpenses
8585305 USD
us-gaap Costs And Expenses
CostsAndExpenses
6020174 USD
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3867074 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2798009 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-7187693 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-5180531 USD
CY2021Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
20900 USD
CY2020Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
146587 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
46570 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
314970 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3846174 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-2651422 USD
us-gaap Net Income Loss
NetIncomeLoss
-7141123 USD
us-gaap Net Income Loss
NetIncomeLoss
-4865561 USD
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.26
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27645366
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27467366
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27589627
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27459415
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
28446561 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
421071 USD
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
115800 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3294949 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
25688483 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
446120 USD
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
870340 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3846174 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
23158769 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
35864471 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
426939 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
175000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-2214139 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
34252271 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
436613 USD
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
55743 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-2651422 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
32093205 USD
us-gaap Net Income Loss
NetIncomeLoss
-7141123 USD
us-gaap Net Income Loss
NetIncomeLoss
-4865561 USD
us-gaap Share Based Compensation
ShareBasedCompensation
867191 USD
us-gaap Share Based Compensation
ShareBasedCompensation
863552 USD
us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
159481 USD
us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
229919 USD
dyai Provision For Contract Losses
ProvisionForContractLosses
0 USD
dyai Provision For Contract Losses
ProvisionForContractLosses
74955 USD
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-46079 USD
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-50204 USD
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
51066 USD
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-103576 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
36049 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-32112 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-179617 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
321533 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1427809 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
154484 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
104546 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-188369 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
135732 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-37268 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4307783 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3903929 USD
us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
11283940 USD
us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
14677156 USD
us-gaap Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
8000000 USD
us-gaap Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
25305000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3283940 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
10627844 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
986140 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
230743 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
986140 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
230743 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-12636 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3347 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6618219 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
6958005 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
20637045 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4823544 USD
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14018826 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11781549 USD
dyai Number Of Research Organizations
NumberOfResearchOrganizations
3 pure
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results <em style="font: inherit;"> may </em>differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Concentrations and Credit Risk</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company’s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, investment securities, and accounts receivable. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”) insured limit on domestic currency and the Netherlands’ FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has <em style="font: inherit;">not</em> experienced any losses in such accounts.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2021 </em>and <em style="font: inherit;">2020</em>, the Company’s revenue was generated from eleven and nine customers, respectively. For the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2021 </em>and <em style="font: inherit;">2020</em>, the Company’s revenue was generate<span style="background-color:#ffffff;">d from thirteen and ten customers, respectively. As of </span><em style="font: inherit;"> June 30, 2021</em><span style="background-color:#ffffff;"> and </span><em style="font: inherit;"> December 31, 2020</em><span style="background-color:#ffffff;">, the Company’s accounts receivable was from eight </span><span style="background-color:#ffffff;">and nine customers, respectively. The loss of business from <em style="font: inherit;">one</em> or a combination of the Company’s customers could adversely affect its operations.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> The Company conducts operations in the Netherlands through its foreign subsidiary and generates a portion of its revenues from customers that are located outside of the United States. For the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months en<span style="background-color:#ffffff;">ded </span><em style="font: inherit;"> June 30, 2021</em><span style="background-color:#ffffff;">, the Company had six and seven customers outside of the United States (i.e. European and Asian customers) that accounted for approximately $797,000 or 85.1% and $1,121,000 or 80.2%</span><span style="background-color:#ffffff;"> of the revenue, respectively. For the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended </span><em style="font: inherit;"> June 30, 2020</em><span style="background-color:#ffffff;">, the Company had four and five</span><span style="background-color:#ffffff;"> customers outside of the United States that accounted for approximately $258,000 or 49.2% and $441,000 or 52.5% of the revenue. </span></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As of <em style="font: inherit;"> June 30, 2021</em>, the Company had three customers outside of the United States (i.e. European and Asian customers) that accounted for approximately $123,000 or 42.1% of accounts receivable. As of <em style="font: inherit;"> December 31, 2020</em>, the Company had seven customers outside of the United States that accounted for approximately $123,000 or 41.6% of accounts receivable.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;"><span style="background-color:#ffffff;">The Company uses several contract research organizations (“CROs”) to conduct its research projects. For the <em style="font: inherit;">three</em> months ended </span><em style="font: inherit;"> June 30, 2021</em><span style="background-color:#ffffff;">, </span>two<span style="background-color:#ffffff;"> CROs accounted for approximately $2,622,000 or 95.8% of total research services we purchased. For the <em style="font: inherit;">six</em> months ended </span><em style="font: inherit;"> June 30, 2021</em><span style="background-color:#ffffff;"> three CROs accounted for approximately $4,639,000 or 96.8% of total research services. For the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended </span><em style="font: inherit;"> June 30, 2020</em><span style="background-color:#ffffff;">, one CRO accounted for approximately $1,618,000, or 93.7% and $2,473,000, or 95.8% of total research services we purchased, respectively. As of <em style="font: inherit;"> June 30, 2021, </em>two CROs accounted for approximately $2,203,000 or 90.5% of the accounts payable. As of </span><em style="font: inherit;"> December 31, 2020</em><span style="background-color:#ffffff;">, one CRO accounted for approximately $690,000 or 68.1% of the accounts payable. The loss of this CRO or a combination of the Company’s CROs could adversely affect its operations.</span></p>
CY2021Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 USD
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
291435 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
294199 USD
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
594803 USD
CY2021Q2 us-gaap Prepaid Insurance
PrepaidInsurance
22319 USD
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
204988 USD
CY2021Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
77663 USD
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
72403 USD
CY2021Q2 us-gaap Prepaid Taxes
PrepaidTaxes
906 USD
CY2020Q4 us-gaap Prepaid Taxes
PrepaidTaxes
3164 USD
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
100888 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
280555 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
13367 USD
CY2021Q2 dyai Research And Development In Process Current
ResearchAndDevelopmentInProcessCurrent
2273607 USD
CY2020Q4 dyai Research And Development In Process Current
ResearchAndDevelopmentInProcessCurrent
904572 USD
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
70695 USD
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
24496 USD
CY2021Q2 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
90632 USD
CY2020Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
84031 USD
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2434934 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1013099 USD
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
276112 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
447881 USD
CY2021Q2 dyai Accrued Research And Development In Process Current
AccruedResearchAndDevelopmentInProcessCurrent
230381 USD
CY2020Q4 dyai Accrued Research And Development In Process Current
AccruedResearchAndDevelopmentInProcessCurrent
28508 USD
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
88310 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
489756 USD
CY2020Q2 dyai Research And Development Expense Including Related Party
ResearchAndDevelopmentExpenseIncludingRelatedParty
1116163 USD
dyai Research And Development Expense Including Related Party
ResearchAndDevelopmentExpenseIncludingRelatedParty
4017340 USD
dyai Research And Development Expense Including Related Party
ResearchAndDevelopmentExpenseIncludingRelatedParty
1871616 USD
CY2021Q2 dyai Research And Development Expense Outside Contracted Services
ResearchAndDevelopmentExpenseOutsideContractedServices
2036753 USD
CY2020Q2 dyai Research And Development Expense Outside Contracted Services
ResearchAndDevelopmentExpenseOutsideContractedServices
970846 USD
dyai Research And Development Expense Outside Contracted Services
ResearchAndDevelopmentExpenseOutsideContractedServices
3695947 USD
dyai Research And Development Expense Outside Contracted Services
ResearchAndDevelopmentExpenseOutsideContractedServices
1584636 USD
CY2021Q2 dyai Research And Development Expense Personnel Related Costs
ResearchAndDevelopmentExpensePersonnelRelatedCosts
149587 USD
CY2020Q2 dyai Research And Development Expense Personnel Related Costs
ResearchAndDevelopmentExpensePersonnelRelatedCosts
139515 USD
dyai Research And Development Expense Personnel Related Costs
ResearchAndDevelopmentExpensePersonnelRelatedCosts
297749 USD
dyai Research And Development Expense Personnel Related Costs
ResearchAndDevelopmentExpensePersonnelRelatedCosts
263153 USD
CY2021Q2 dyai Research And Development Expense Facilities Overhead And Other
ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther
22902 USD
CY2020Q2 dyai Research And Development Expense Facilities Overhead And Other
ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther
5802 USD
dyai Research And Development Expense Facilities Overhead And Other
ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther
23644 USD
dyai Research And Development Expense Facilities Overhead And Other
ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther
23827 USD
CY2021Q2 dyai Research And Development Expense Including Related Party
ResearchAndDevelopmentExpenseIncludingRelatedParty
2209242 USD
CY2020Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
22473 USD
CY2020Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
6463 USD
CY2021Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2021Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
12600000 USD
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
9400000 USD
dyai Deferred Tax Assets Valuation Allowance Coverage Percent
DeferredTaxAssetsValuationAllowanceCoveragePercent
1 pure
CY2020Q4 us-gaap Investments And Cash
InvestmentsAndCash
29094496 USD
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4799215
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4650390
CY2017Q2 dyai Collaborative Arrangement Payment For Research And Development Agreement
CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement
1100000 USD
CY2021Q2 us-gaap Cash
Cash
820985 USD
CY2021Q2 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
13197841 USD
CY2021Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
14018826 USD
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14018826 USD
CY2021Q2 dyai Cash Cash Equivalents And Investments Fair Value
CashCashEquivalentsAndInvestmentsFairValue
25589160 USD
CY2021Q2 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
0 USD
CY2021Q2 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
11577 USD
CY2021Q2 us-gaap Investments And Cash
InvestmentsAndCash
25600737 USD
CY2020Q4 us-gaap Cash
Cash
149015 USD
CY2020Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
20488030 USD
CY2020Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
20637045 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20637045 USD
CY2020Q4 dyai Cash Cash Equivalents And Investments Fair Value
CashCashEquivalentsAndInvestmentsFairValue
29110506 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0013 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0055 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.5452 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.5607 pure
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3491141
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.38
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y6M10D
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
5472602 USD
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4638390
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.44
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y7M20D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
13701610 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
745825
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.25
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
585000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.68
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4799215
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.97
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y4M13D
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
5965132 USD
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
446120 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
436613 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
867191 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
863552 USD
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.68
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.88
CY2021Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
12253502
CY2021Q2 us-gaap Treasury Stock Value
TreasuryStockValue
18900000 USD
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001

Files In Submission

Name View Source Status
0001437749-21-019688-index-headers.html Edgar Link pending
0001437749-21-019688-index.html Edgar Link pending
0001437749-21-019688.txt Edgar Link pending
0001437749-21-019688-xbrl.zip Edgar Link pending
dyai-20200930_g1copy.jpg Edgar Link pending
dyai-20210630.xsd Edgar Link pending
dyai-20210630_cal.xml Edgar Link unprocessable
dyai-20210630_def.xml Edgar Link unprocessable
dyai-20210630_lab.xml Edgar Link unprocessable
dyai-20210630_pre.xml Edgar Link unprocessable
dyai20210630_10q.htm Edgar Link pending
dyai20210630_10q_htm.xml Edgar Link completed
ex_250813.htm Edgar Link pending
ex_250814.htm Edgar Link pending
ex_250815.htm Edgar Link pending
ex_250816.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending